Dr. Reddy's Laboratories Ltd. (RDY)
Summary
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety concerns.
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.
Dr. Reddy's Laboratories Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 161 | $2,167.45 | $2,072.07 | -$95.38 | -4.4% |
| YA Yinka Akinsola Blue Trust Inc. | 32,637 | $447,829.81 | $418,732.71 | -$29,097.1 | -6.5% |
| MD Michelle Dubey Yousif Capital Management LLC | 12,785 | $203,153.65 | $163,264.45 | -$39,889.2 | -19.63% |
 Jennifer Easley Gitterman Wealth Management LLC | 17,512 | $264,961.58 | $225,204.32 | -$39,757.26 | -15% |
 Jeffery Yorg Focus Partners Advisor Solutions LLC | 12,503 | $174,791.94 | $160,413.49 | -$14,378.45 | -8.23% |
Dr. Reddy's Laboratories Ltd. (RDY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dr. Reddy's Laboratories Ltd. ever had a stock split?
Dr. Reddy's Laboratories Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Erez Israeli CEO | NYSE Exchange | 256135203 CUSIP |
| IN Country | 27,527 Employees | 24 Jul 2026 Last Dividend | 7 Sep 2006 Last Split | 11 Apr 2001 IPO Date |
Overview
Dr. Reddy's Laboratories Limited represents a multifaceted pharmaceutical entity with a global footprint, engaging in an integrated range of pharmaceutical activities. Established in 1984 and based in Hyderabad, India, the company maintains a broad operation spectrum through its distinct segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. These segments underline the company's diversified approach, encompassing the production and marketing of generic and branded pharmaceutical products, active pharmaceutical ingredients (APIs), and contract research services, along with a focused effort on developing therapies in oncology and inflammation. Their commitment to innovation and quality places them among the leading pharmaceutical companies worldwide.
Products and Services
- Global Generics
This segment is pivotal in manufacturing and marketing prescription and over-the-counter pharmaceutical products, available both under brand names and as generic formulations equivalent to branded counterparts. Dr. Reddy’s has made significant strides in the biologics domain under this segment, indicating a strong emphasis on advancing therapeutic solutions and accessibility.
- Pharmaceutical Services and Active Ingredients (PSAI)
A crucial arm of Dr. Reddy’s, the PSAI segment is responsible for the manufacturing and marketing of active pharmaceutical ingredients and intermediates – the essential components for finishing pharmaceutical products. Notably, it extends contract research services, catering to the diverse requirements of customers by providing custom synthesized APIs and steroids. This segment underscores the company’s role as a vital player in the pharmaceutical value chain, bolstering the global supply of key pharmaceutical ingredients.
- Others
Under this segment, Dr. Reddy's delineates its focus on the research and development department, particularly in crafting therapies for oncology and inflammation. Additionally, it embarks on the development of differentiated formulations aimed at enhancing therapeutic efficacy and patient compliance. Another noteworthy area within this segment is their investment in digital healthcare solutions and IT-enabled business support services, demonstrating a forward-looking approach to adapting in an increasingly digitalized healthcare landscape.
